Analyst Coverage
Immunovaccine Inc. is followed by the analyst(s) listed below. Please note that any opinions, estimates or forecasts regarding Immunovaccine’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Immunovaccine Inc. or its management.
Beacon Securities Ltd.
Analyst: Sarah Chiasson Tel: 902.425.6654
Beacon Securities initiated coverage December 4th, 2009
To access the report visit www.beaconsecurities.ca/login.asp
Click here to view Beacon Securities Q4 2009 Quarterly Report
Paradigm Capital Inc.
Senior Analyst: Claude Camiré Tel: 416.360.1322
Paradigm Capital initated coverage Feb. 26, 2010
To access the report visit www.paradigmcapinc.com/research
Immunovaccine (TSX-V: IMV) is a clinical stage biotechnology company developing infectious disease and therapeutic cancer vaccines for human health. The company continues to strengthen its vaccine pipeline through licensing and strategic partnering. With positive pre-clinical safety data and recent partnerships with LIAI, NIH, Yokohoma City University, Defence Research & Development Canada, FIT Biotech and NCI the value of their Depovax™ vaccine delivery system has been significantly enhanced.
Click Here to visit Immunovaccine's Document Library. The Document Library is available to all current and potential investors and partners
For further information about investment in Immunovaccine, please contact Brian Lowe, Vice President at